The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
The 2022 Tandem Meetings | Exciting CAR-T data in multiple myeloma and follicular lymphoma: CARTITUDE-2, ELARA & ZUMA-5
Bhagirathbhai Dholaria, MBBS, Vanderbilt University Medical Center, Nashville, TN, shares his thoughts on the most exciting data in CAR-T therapy that has been released at this year’s Tandem Meetings, including results from the CARTITUDE-2 (NCT04133636), ELARA (NCT03568461), and ZUMA-5 (NCT03105336) studies. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
